| Description |
1 online resource |
| Contents |
Clinical Heterogeneity of ALS -- Implications for Models and Therapeutic Development / Serena Lattante and Mario Sabatelli -- Genetic Basis of ALS / Jay P. Ross, Patrick A. Dion, and Guy A. Rouleau -- Susceptibility Genes and Epigenetics in Sporadic ALS / Jessica R. Morrice, Christopher A. Shaw -- The Lessons of ALS -- PDC -- Environmental Factors in ALS Etiology / Christopher A. Shaw and Thomas E. Marler -- The Microbiome of ALS -- Does It Start from the Gut? / Audrey Labarre and Alex Parker -- Protein Aggregation in Amyotrophic Lateral Sclerosis / Christen G. Chisholm, Justin J. Yerbury, and Luke McAlary -- Evidence for a Growing Involvement of Glia in Amyotrophic Lateral Sclerosis / Rowan A. W. Radford, Andres Vidal-Itriago, Natalie M. Scherer, Albert Lee, Manuel Graeber, Roger S. Chung, and Marco Morsch -- Animal Models of ALS -- Current and Future Perspectives / Robert A. Déziel, Amber L. Marriott, Denis G. Kay, and Daphne A. Gill -- Clinical Trials in ALS -- Current Challenges and Strategies for Future Directions / Kristiana Salmon and Angela Genge -- Future Priorities and Directions in ALS Research and Treatment / Jessica R. Morrice, Michael Kuo, and Christopher A. Shaw |
| Summary |
"Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disorder affecting both upper and lower motor neurons. Based on age at onset, site of onset, disease duration, and relative predominance of upper or lower motor neuron signs, clinical manifestations of ALS are very heterogeneous, and different clinical subtypes may be delineated. Although ALS has long been considered a paradigm of pure motor neuron disorder, it has recently been linked to other neurological diseases. Clinical, genetic, and/or neuropathological overlap exists with frontotemporal dementia, distal myopathies, psychiatric disorders, and extrapyramidal syndromes. This clinical heterogeneity can depend on the pleiotropy of ALS-associated genes and by the oligogenic model of disease mechanism. A number of animal models have been created, each of them recapitulating some clinical and neuropathological features of patients. More recently, induced pluripotent stem cells have been used, directly derived from affected patients with different genetic mutations. The combination of animal and cellular models represents an advanced tool that can help to functionally characterize the pathogenetic mechanisms underlying the disease and specifically find efficient and personalized drugs to treat ALS patients"-- Provided by publisher |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Description based on print version record and CIP data provided by publisher; resource not viewed |
| Subject |
Amyotrophic Lateral Sclerosis -- genetics
|
|
Amyotrophic Lateral Sclerosis -- drug therapy
|
|
Genetic Heterogeneity
|
|
Models, Genetic
|
|
Spectrum Analysis
|
|
Amyotrophic lateral sclerosis -- Chemotherapy
|
|
Amyotrophic lateral sclerosis -- Genetic aspects
|
| Form |
Electronic book
|
| Author |
Morrice, Jessica R., editor.
|
|
Shaw, Christopher A. (Christopher Ariel), editor.
|
| LC no. |
2021003407 |
| ISBN |
1119745500 |
|
1119745519 |
|
1119745535 |
|
9781119745501 |
|
9781119745518 |
|
9781119745532 |
|
